Declining rates of treatment-related mortality in patients with newly diagnosed AML given 'intense' induction regimens: a report from SWOG and MD Anderson.
about
Improvements in the early death rate among 9380 patients with acute myeloid leukemia after initial therapy: A SEER database analysisThe Broad Anti-AML Activity of the CD33/CD3 BiTE Antibody Construct, AMG 330, Is Impacted by Disease Stage and RiskPostinduction Supportive Care of Pediatric Acute Myelocytic Leukemia: Should Patients be Kept in the Hospital?Acute myeloid leukemia: 2014 update on risk-stratification and management.Management of older or unfit patients with acute myeloid leukemiaFate of patients with newly diagnosed acute myeloid leukemia who fail primary induction therapy.Prediction of adverse events during intensive induction chemotherapy for acute myeloid leukemia or high-grade myelodysplastic syndromes.A randomized comparison of daunorubicin 90 mg/m2 vs 60 mg/m2 in AML induction: results from the UK NCRI AML17 trial in 1206 patients.Resource Utilization and Safety of Outpatient Management Following Intensive Induction or Salvage Chemotherapy for Acute Myeloid Leukemia or Myelodysplastic Syndrome: A Nonrandomized Clinical Comparative Analysis.Incorporating measurable ('minimal') residual disease-directed treatment strategies to optimize outcomes in adults with acute myeloid leukemia.Outcome of adolescents and young adults with acute myeloid leukemia treated on COG trials compared to CALGB and SWOG trials.Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel.Outpatient care of patients with acute myeloid leukemia: Benefits, barriers, and future considerationsManagement of Acute Myeloid Leukemia in the Intensive Care Setting.Update on antigen-specific immunotherapy of acute myeloid leukemia.Management of Newly Diagnosed Acute Myeloid Leukemia in the Elderly: Current Strategies and Future Directions.Bloodstream infections in acute myeloid leukemia patients treated according to the Finnish Leukemia Group AML-2003 protocol - a prospective nationwide study.The artful management of older patients with acute myeloid leukemia.High feasibility and antileukemic efficacy of fludarabine, cytarabine, and idarubicin (FLAI) induction followed by risk-oriented consolidation: A critical review of a 10-year, single-center experience in younger, non M3 AML patients.Early mortality and complications in hospitalized adult Californians with acute myeloid leukaemia.Acute myeloid leukemia: 2016 Update on risk-stratification and management.Treatment of Elderly Patients With Acute Myeloid Leukemia.Association of Risk Factors, Mortality, and Care Costs of Adults With Acute Myeloid Leukemia With Admission to the Intensive Care Unit.Predicting Chemotherapy Resistance in AML.Karyotype plus NPM1 mutation status defines a group of elderly patients with AML (≥60 years) who benefit from intensive post-induction consolidation therapy.Ciprofloxacin prophylaxis delays initiation of broad-spectrum antibiotic therapy and reduces the overall use of antimicrobial agents during induction therapy for acute leukaemia: A single-centre study.TP53 mutations in older adults with acute myeloid leukemia.Prediction of early death in adults with relapsed or refractory acute myeloid leukemia.Long-term follow-up of the AML97 study for patients aged 60 years and above with acute myeloid leukaemia: a study of the East German Haematology and Oncology Study Group (OSHO).A comparative study of bloodstream infections in acute myeloid leukemia according to different phases of treatment: Can we predict the organism?The treatment-related mortality score is associated with non-fatal adverse events following intensive AML induction chemotherapyAcute myeloid leukaemia.Pre-treatment with oral hydroxyurea prior to intensive chemotherapy improves early survival of patients with high hyperleukocytosis in acute myeloid leukemia.
P2860
Q27336142-D043AC1A-955C-4754-8D7C-381E7843B26EQ28547458-29E434A2-4B5B-4593-9289-C5F906CA7B16Q34346926-405AA8B9-15F2-4AA8-A74B-8DCA3FCD414BQ34665691-43E78D49-5D12-4678-89B6-B96317323E5CQ34893307-F63A693F-8C41-4B26-AC25-EC6D7EB0949AQ35285004-276B6092-8834-41F7-93C2-40D9EA506EADQ35343940-EE6A4A20-DD13-406A-B39F-18D33A3EF7DCQ35859437-D8D406DF-50D8-4A2E-983C-1C2D20A98B30Q36485407-A2E9592D-CBE2-444A-848F-88C239A8796EQ37141503-A327A734-07AE-44CB-B053-33F4481B0FA8Q37324869-E7BCE43D-4870-4949-9847-8515BD494ADFQ37624593-896EEA37-2DBF-4BFF-A330-B258AAD381D1Q37740176-E863ABE7-FEA7-4240-8CCE-D7D065238195Q38206394-539D2130-7A7A-40FD-99F8-45DD0A12A5A0Q38432103-DFA8E5E6-213B-4AD4-B32D-3C44F818A666Q38601723-BE4F1042-D6B4-42B3-847B-61E9335AEDD6Q38690746-6BFA900C-6093-48E3-9D00-B5A4499D8C65Q38734206-D0B4700C-8F5C-45F3-9611-469FF4A2B5AAQ38809840-16734E62-5CEF-4B4F-A164-154353DA2DA4Q38832223-9D3D0C14-CA1F-4B13-8C4B-316440412044Q38897289-6FC49CBE-AD37-4FE5-8898-A9EA37CB12FFQ39112940-E49A2ED4-8E9A-48A0-B659-9CC8058C912FQ39198600-22D21E48-B99F-4EA7-87AE-F152BD9AFEC8Q39233284-3E2CF0F0-0C38-488D-95CF-5FD1A6F20B00Q40575708-FA4A4E61-7CE3-4677-9E64-D1772084040CQ40734670-7F07E175-85A0-4D96-9D60-2CEC714179D4Q40967841-23DC7825-E0D1-4ADA-BF5C-2CE5E8D00557Q40985601-C41597E5-8E88-4A98-B8E7-5F6C44FE9759Q41313041-F17DA251-7F5A-4B9D-A8B7-B472ED70F9E1Q41928196-1752ACA7-BA4D-4B07-9B3A-F129ED045BCBQ42358970-C6814F71-BA8B-4AD9-9646-529851B47EB8Q47432401-41BBCB3C-7C2F-4EF4-A1AF-7133C68F24F7Q50883085-7F2CA453-258D-419F-B6DD-13D70601ED89
P2860
Declining rates of treatment-related mortality in patients with newly diagnosed AML given 'intense' induction regimens: a report from SWOG and MD Anderson.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Declining rates of treatment-r ...... ort from SWOG and MD Anderson.
@en
type
label
Declining rates of treatment-r ...... ort from SWOG and MD Anderson.
@en
prefLabel
Declining rates of treatment-r ...... ort from SWOG and MD Anderson.
@en
P2093
P2860
P356
P1433
P1476
Declining rates of treatment-r ...... ort from SWOG and MD Anderson.
@en
P2093
H Kantarjian
S Petersdorf
P2860
P2888
P304
P356
10.1038/LEU.2013.176
P577
2013-06-13T00:00:00Z
P6179
1009173449